Molecular markers of gliomas

A clinical approach

M. Eoli, A. Silvani, B. Pollo, D. Bianchessi, F. Menghi, L. Valletta, G. Broggi, A. Boiardi, M. G. Bruzzone, G. Finocchiaro

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Over the last decade, the knowledge on the molecular genetic background of gliomas has dramatically increased. This information provides the basis for the molecular target therapies and molecular tests serve to complement the subjective nature of histopathologic criteria and add useful data regarding response to treatments and prognosis. In particular, the use of loss of heterozygosity (LOH) and methylation specific polymerase chain reaction (PCR) (MSP) based testing of gliomas is already in place and used clinically in several centers. This paper provides a brief overview of these molecular genetic aberrations and discusses the clinical utility, as well as the advantages and disadvantages of such approach. Newly developed molecular techniques, such as LOH testing, fluorescence in situ hybridization (FISH), DNA sequencing and MSP, are currently being employed in assessment of gliomas in some laboratories. However, the clinical use of some markers and the context in which the information obtained should be used are still not entirely understood. Therefore, this paper will focus on validation and implementation of molecular testing in gliomas, with emphasis on LOH on chromosomes 1p, 19q, 17p and 10q and O6-methylguanine-DNA methyltransferase (MGMT) methylation status. 538-541

Original languageEnglish
Pages (from-to)538-541
Number of pages4
JournalNeurological Research
Volume28
Issue number5
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Glioma
Loss of Heterozygosity
Molecular Biology
Methyltransferases
DNA Methylation
Fluorescence In Situ Hybridization
DNA Sequence Analysis
Methylation
Chromosomes
Polymerase Chain Reaction
Therapeutics

Keywords

  • Glioblastoma
  • Glioma
  • LOH 1p/19q
  • MRI
  • Oligoastrocytoma
  • Oligodendroglioma
  • TP53 mutations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Molecular markers of gliomas : A clinical approach. / Eoli, M.; Silvani, A.; Pollo, B.; Bianchessi, D.; Menghi, F.; Valletta, L.; Broggi, G.; Boiardi, A.; Bruzzone, M. G.; Finocchiaro, G.

In: Neurological Research, Vol. 28, No. 5, 07.2006, p. 538-541.

Research output: Contribution to journalArticle

Eoli, M. ; Silvani, A. ; Pollo, B. ; Bianchessi, D. ; Menghi, F. ; Valletta, L. ; Broggi, G. ; Boiardi, A. ; Bruzzone, M. G. ; Finocchiaro, G. / Molecular markers of gliomas : A clinical approach. In: Neurological Research. 2006 ; Vol. 28, No. 5. pp. 538-541.
@article{6add65712bac45e58bb541cc324a3ce3,
title = "Molecular markers of gliomas: A clinical approach",
abstract = "Over the last decade, the knowledge on the molecular genetic background of gliomas has dramatically increased. This information provides the basis for the molecular target therapies and molecular tests serve to complement the subjective nature of histopathologic criteria and add useful data regarding response to treatments and prognosis. In particular, the use of loss of heterozygosity (LOH) and methylation specific polymerase chain reaction (PCR) (MSP) based testing of gliomas is already in place and used clinically in several centers. This paper provides a brief overview of these molecular genetic aberrations and discusses the clinical utility, as well as the advantages and disadvantages of such approach. Newly developed molecular techniques, such as LOH testing, fluorescence in situ hybridization (FISH), DNA sequencing and MSP, are currently being employed in assessment of gliomas in some laboratories. However, the clinical use of some markers and the context in which the information obtained should be used are still not entirely understood. Therefore, this paper will focus on validation and implementation of molecular testing in gliomas, with emphasis on LOH on chromosomes 1p, 19q, 17p and 10q and O6-methylguanine-DNA methyltransferase (MGMT) methylation status. 538-541",
keywords = "Glioblastoma, Glioma, LOH 1p/19q, MRI, Oligoastrocytoma, Oligodendroglioma, TP53 mutations",
author = "M. Eoli and A. Silvani and B. Pollo and D. Bianchessi and F. Menghi and L. Valletta and G. Broggi and A. Boiardi and Bruzzone, {M. G.} and G. Finocchiaro",
year = "2006",
month = "7",
doi = "10.1179/016164106X116827",
language = "English",
volume = "28",
pages = "538--541",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Molecular markers of gliomas

T2 - A clinical approach

AU - Eoli, M.

AU - Silvani, A.

AU - Pollo, B.

AU - Bianchessi, D.

AU - Menghi, F.

AU - Valletta, L.

AU - Broggi, G.

AU - Boiardi, A.

AU - Bruzzone, M. G.

AU - Finocchiaro, G.

PY - 2006/7

Y1 - 2006/7

N2 - Over the last decade, the knowledge on the molecular genetic background of gliomas has dramatically increased. This information provides the basis for the molecular target therapies and molecular tests serve to complement the subjective nature of histopathologic criteria and add useful data regarding response to treatments and prognosis. In particular, the use of loss of heterozygosity (LOH) and methylation specific polymerase chain reaction (PCR) (MSP) based testing of gliomas is already in place and used clinically in several centers. This paper provides a brief overview of these molecular genetic aberrations and discusses the clinical utility, as well as the advantages and disadvantages of such approach. Newly developed molecular techniques, such as LOH testing, fluorescence in situ hybridization (FISH), DNA sequencing and MSP, are currently being employed in assessment of gliomas in some laboratories. However, the clinical use of some markers and the context in which the information obtained should be used are still not entirely understood. Therefore, this paper will focus on validation and implementation of molecular testing in gliomas, with emphasis on LOH on chromosomes 1p, 19q, 17p and 10q and O6-methylguanine-DNA methyltransferase (MGMT) methylation status. 538-541

AB - Over the last decade, the knowledge on the molecular genetic background of gliomas has dramatically increased. This information provides the basis for the molecular target therapies and molecular tests serve to complement the subjective nature of histopathologic criteria and add useful data regarding response to treatments and prognosis. In particular, the use of loss of heterozygosity (LOH) and methylation specific polymerase chain reaction (PCR) (MSP) based testing of gliomas is already in place and used clinically in several centers. This paper provides a brief overview of these molecular genetic aberrations and discusses the clinical utility, as well as the advantages and disadvantages of such approach. Newly developed molecular techniques, such as LOH testing, fluorescence in situ hybridization (FISH), DNA sequencing and MSP, are currently being employed in assessment of gliomas in some laboratories. However, the clinical use of some markers and the context in which the information obtained should be used are still not entirely understood. Therefore, this paper will focus on validation and implementation of molecular testing in gliomas, with emphasis on LOH on chromosomes 1p, 19q, 17p and 10q and O6-methylguanine-DNA methyltransferase (MGMT) methylation status. 538-541

KW - Glioblastoma

KW - Glioma

KW - LOH 1p/19q

KW - MRI

KW - Oligoastrocytoma

KW - Oligodendroglioma

KW - TP53 mutations

UR - http://www.scopus.com/inward/record.url?scp=33746504858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746504858&partnerID=8YFLogxK

U2 - 10.1179/016164106X116827

DO - 10.1179/016164106X116827

M3 - Article

VL - 28

SP - 538

EP - 541

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 5

ER -